U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H44N8O4
Molecular Weight 664.7965
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENEBRUTINIB

SMILES

C[C@H]1CN(CCN1C2=CN=C(NC3=CC(=CN(C)C3=O)C4=CC=NC(N5CCN6C(=CC7=C6CC(C)(C)C7)C5=O)=C4CO)C=C2)C8COC8

InChI

InChIKey=WNEODWDFDXWOLU-QHCPKHFHSA-N
InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1

HIDE SMILES / InChI
G-0853 (also GDC-0853, or Fenebrutinib) is a potent, selective, orally administered, and noncovalent Bruton's tyrosine kinase (Btk) inhibitor currently in clinical development. Upon administration, G-0853 inhibits the activity of Btk and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and Btk-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK is overexpressed in B-cell malignancies, and plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival. G-0853 suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis. G-0853 demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclinical and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q06187
Gene ID: 695.0
Gene Symbol: BTK
Target Organism: Homo sapiens (Human)
Name Type Language
FENEBRUTINIB
INN   USAN  
Official Name English
G-02599853
Code English
fenebrutinib [INN]
Common Name English
RG-7845
Code English
RO7010939
Code English
RG7845
Code English
GDC-0853
Code English
G02599853
Code English
RO-7010939
Code English
2H-CYCLOPENTA(4,5)PYRROLO(1,2-A)PYRAZIN-1(6H)-ONE, 2-(1,6-DIHYDRO-3'-(HYDROXYMETHYL)-1-METHYL-5-((5-((2S)-2-METHYL-4-(3-OXETANYL)-1-PIPERAZINYL)-2-PYRIDINYL)AMINO)-6-OXO(3,4'-BIPYRIDIN)-2'-YL)-3,4,7,8-TETRAHYDRO-7,7-DIMETHYL-
Systematic Name English
FENEBRUTINIB [USAN]
Common Name English
(S)-2-(3'-(HYDROXYMETHYL)-1-METHYL-5-((5-(2-METHYL- 4-(OXETAN-3-YL)PIPERAZIN-1-YL)PYRIDIN-2-YL)AMINO)-6-OXO-1,6-DIHYDRO-(3,4'-BIPYRIDIN)-2'-YL)-7,7-DIMETHYL-2,3,4,6,7,8-HEXAHYDRO-1H-CYCLOPENTA (4,5)PYRROLO(1,2-A)PYRAZIN-1-ONE
Systematic Name English
Fenebrutinib [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 08:26:24 GMT 2023 , Edited by admin on Sat Dec 16 08:26:24 GMT 2023
NCI_THESAURUS C124801
Created by admin on Sat Dec 16 08:26:24 GMT 2023 , Edited by admin on Sat Dec 16 08:26:24 GMT 2023
Code System Code Type Description
USAN
EF-62
Created by admin on Sat Dec 16 08:26:24 GMT 2023 , Edited by admin on Sat Dec 16 08:26:24 GMT 2023
PRIMARY
CAS
1434048-34-6
Created by admin on Sat Dec 16 08:26:24 GMT 2023 , Edited by admin on Sat Dec 16 08:26:24 GMT 2023
PRIMARY
INN
10603
Created by admin on Sat Dec 16 08:26:24 GMT 2023 , Edited by admin on Sat Dec 16 08:26:24 GMT 2023
PRIMARY
DRUG BANK
DB14785
Created by admin on Sat Dec 16 08:26:24 GMT 2023 , Edited by admin on Sat Dec 16 08:26:24 GMT 2023
PRIMARY
FDA UNII
E9L2885WUL
Created by admin on Sat Dec 16 08:26:24 GMT 2023 , Edited by admin on Sat Dec 16 08:26:24 GMT 2023
PRIMARY
SMS_ID
100000175821
Created by admin on Sat Dec 16 08:26:24 GMT 2023 , Edited by admin on Sat Dec 16 08:26:24 GMT 2023
PRIMARY
NCI_THESAURUS
C116844
Created by admin on Sat Dec 16 08:26:24 GMT 2023 , Edited by admin on Sat Dec 16 08:26:24 GMT 2023
PRIMARY
PUBCHEM
86567195
Created by admin on Sat Dec 16 08:26:24 GMT 2023 , Edited by admin on Sat Dec 16 08:26:24 GMT 2023
PRIMARY